Results 201 to 210 of about 72,887 (326)

Effect of a poly(ADP‐ribose) polymerase‐1 inhibitor against esophageal squamous cell carcinoma cell lines [PDF]

, 2013
Tomomitsu Nasuno, Sachiyo Mimaki, Makito Okamoto, Hiroyasu Esumi, Katsuya Tsuchihara   +4 more
openalex   +1 more source

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]

Oncotarget, 2022
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B.   +17 more
europepmc   +1 more source

Unveiling Immune System Perturbations in Early Development Through Zebrafish Models of NADHX Repair Deficiency

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT The vital cofactors NADH and NADPH are prone to hydration, forming hydroxylated redox‐inactive derivatives (NADHX and NADPHX) in cells. These damaged metabolites are repaired by two highly conserved enzymes, an NAD(P)HX dehydratase (NAXD) and an NAD(P)HX epimerase (NAXE).
Myrto Patraskaki, Najmesadat Seyedkatouli, Lisa Schlicker, Marc O. Warmoes, Maria Lorena Cordero‐Maldonado, Ursula Heins‐Marroquin, Carole L. Linster   +6 more
wiley   +1 more source

Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors

, 2009
Federica Orvieto, Danila Branca, Claudia Giomini, Philip Jones, Uwe Koch, Jesus M. Ontoria, Maria Cecilia Palumbi, Michael Rowley, Carlo Toniatti, Ester Muraglia   +9 more
openalex   +1 more source

Long‐lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP‐ribose) polymerase [PDF]

, 2011
Flavio Moroni, Andrea Cozzi, Alberto Chiarugi, Laura Formentini, Emidio Camaioni, Domenico E. Pellegrini‐Giampietro, Y Chen, Liang Shi, MM Zaleska, Cathleen Gonzales, Andrew Wood, R. Pellicciari   +11 more
openalex   +1 more source

Exploring the Key Role of Nanotechnology on Intratumoral Microbiome Modulation for Cancer Immunotherapy

MedComm – Biomaterials and Applications, Volume 5, Issue 1, March 2026.
The review provides a comprehensive analysis of microbiome‐mediated oncogenic mechanisms in various cancers, emphasizing the unique therapeutic strategies facilitated by nanotechnology. It aims to fill this gap by systematically reviewing nanotechnology‐driven strategies for microbiome elimination, with a focus on their ability to improve the cold TME ...
Yumei Gan, Yan Zhang, Xia Dong, Feng Lv
wiley   +1 more source

U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer

, 2019
Joseph Dottino, Haley Moss, Karen H. Lu, Angeles Alvarez Secord, Laura J. Havrilesky   +4 more
openalex   +2 more sources

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

Curr Breast Cancer Rep
Ray A, Opyrchal M.
europepmc   +1 more source

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. [PDF]

Cochrane Database Syst Rev, 2021
Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.   +6 more
europepmc   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source